Biotech

ABBVie (NYSE: ABBV) and Teneobio, Inc. announced today that ABBVie exercised its exclusive right to acquire TeneoOne, an affiliate of Teneobio, Inc., and TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of relapsed or refractory multiple myeloma (RR MM). In February 2019 ABBVie and TeneoOne entered a strategic transaction to develop and commercialize TNB-383B, a bispecific antibody that simultaneously targets BCMA and CD3 and is designed to direct the body's own immune system to target and kill BCMA-expressing tumor cells. ABBVie exercised its exclusive right to acquire TeneoOne and TNB-383B based on an interim analysis of an ongoing Phase 1 study.

Interim results from the ongoing Phase 1 study demonstrated an objective response rate (ORR) of 79 percent, very good partial response (VGPR) or better of 63 percent, and complete response (CR) of 29 percent at doses ≥40 mg in the dose escalation cohorts with a median follow-up time of 6.1 months (n=24). The median duration of response (DOR) has not been reached.

"Since the beginning of this partnership, we have been encouraged by the potential of TNB-383B as a promising new therapy for multiple myeloma, and our analysis of the Phase 1 data to date has allowed us to make this decision with confidence," said Michael Severino , M.D., vice chairman and president, AbbVie. "While other BCMA and CD3 bispecific therapies require weekly administration, the recommended Phase 2 dose of TNB-383B will investigate infrequent dosing of every 3 weeks for intravenous administration, which is an important treatment factor for people living with multiple myeloma."

In this interim analysis, the most frequent treatment emergent adverse events observed across all grades were cytokine release syndrome (CRS) (52 percent), fatigue (25 percent), and neutropenia (24 percent). At the recommended Phase 2 dose of 60 mg administered intravenously every three weeks (Q3W), the CRS rate was 67 percent (all grades) with a grade ≥3 CRS rate of 3 percent (1/39 subjects). No CRS of grade 4 or higher was observed. Onset of CRS generally occurred on the same or next day following the first dose.

"Our aim in developing TNB-383B and our T-cell redirecting anti-CD3 platform is to maximize the therapeutic window of a class of therapeutic molecules that have been clinically challenged by dose-limiting toxicities," said Roland Buelow , CEO of Teneobio, Inc. "AbbVie recognized the potential of Teneobio's platform and shared our vision to assess its clinical validation. The clinical data support the unique features of TNB-383B and our T-cell redirecting CD3 platform. We are confident that AbbVie is the right partner to rapidly develop TNB-383B with the ultimate goal to bring this potential new therapy to myeloma patients in need."

This first-in-human, ongoing Phase 1 monotherapy dose escalation and expansion study evaluates the safety, clinical pharmacology, and clinical activity of TNB-383B in patients with R/R MM who have received at least three prior lines of therapy. The study consists of two portions, a monotherapy dose escalation arm and a monotherapy dose expansion arm. At the interim analysis, 103 subjects have been treated with TNB-383B.

The acquisition is subject to customary closing conditions, including clearance by the U.S. antitrust authorities under the Hart-Scott-Rodino Act.

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com . Follow @abbvie on Twitter , Facebook , Instagram , YouTube and LinkedIn .

Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan plc ("Allergan"), failure to promptly and effectively integrate Allergan's businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2020 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

About Teneobio, Inc.
Teneobio, Inc. is a clinical stage biotechnology company developing a new class of biologics, Human Heavy-Chain Antibodies (UniAb®), for the treatments of cancer, autoimmunity, and infectious diseases. ' 'Teneobio's discovery platform, TeneoSeek, comprises genetically engineered animals (UniRat® and OmniFlic®), next-generation sequencing, bioinformatics and high-throughput vector assembly technologies. TeneoSeek rapidly identifies large numbers of unique binding molecules specific for therapeutic targets of interest. Versatile antibody variable domains (UniDab®) derived from UniAb® can be assembled into multi-specific and multivalent therapeutic proteins, surpassing limitations of conventional antibody therapeutics. 'Teneobio's "plug-and-play" T-cell engaging platform includes a diverse set of anti-CD3 antibodies for therapeutics with optimal efficacy and reduced toxicity.

For more information, please visit www.teneobio.com .

Cision View original content: http://www.prnewswire.com/news-releases/abbvie-exercises-right-to-acquire-teneoone-and-lead-asset-tnb-383b-for-the-potential-treatment-of-relapsed-or-refractory-multiple-myeloma-301318965.html

SOURCE AbbVie

News Provided by PR Newswire via QuoteMedia

Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy to Address Inequities in HIV Care

Gilead Will Provide $4.5 Million in Funding to Help Improve Health Outcomes for Black Americans in the Southern United States –

– Investment Reflects Gilead's Broad and Ongoing Commitment to Advancing Health Equity –

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Experience the JUVÉDERM® Difference with Allergan Aesthetics

Allē Double Point Promotion Encourages Consumers to See the JUVÉDERM ® Difference

Allergan Aesthetics, an ABBVie company (NYSE: ABBV), invites consumers to experience the JUVÉDERM ® difference. The JUVÉDERM ® Collection of Fillers is the number one selling collection of dermal fillers on the market and offers the largest portfolio of fillers specifically designed for different areas of the face to address key patient concerns, enabling a customized treatment approach. 1 Injectable dermal fillers are highly sought-after treatments among consumers who are looking to address key signs of aging or to simply accentuate what is already naturally theirs.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio

Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of Turning Point Therapeutics, Inc. ("Turning Point"), in an all-cash transaction. With the completion of the acquisition, Turning Point shares have ceased trading on the NASDAQ Global Select Market and Turning Point is now a wholly owned subsidiary of Bristol Myers Squibb.

"Turning Point has distinguished itself in the field of precision oncology, and this acquisition will further strengthen our leading oncology franchise," said Elizabeth Mily, Executive Vice President, Strategy & Business Development, Bristol Myers Squibb. "With Turning Point's lead asset, repotrectinib, Bristol Myers Squibb will be positioned to address a significant unmet medical need for ROS1-positive non-small cell lung cancer patients. We look forward to bringing this promising, innovative medicine to patients in the second half of 2023."

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Therapeutics

Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) ("Turning Point") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"), and the receipt of merger control clearance from the Federal Cartel Office of Germany ("FCO"), in connection with the previously announced offer (the "Offer") to acquire all outstanding shares of common stock of Turning Point at a price of $76.00 per share in an all-cash transaction for total consideration of approximately $4.1 billion. The expiration of the HSR Act waiting period occurred at 11:59 p.m. Eastern Time on August 15, 2022, and the FCO clearance was received on August 15, 2022. The Offer expired at 5:00 p.m. Eastern Time on August 15, 2022 (the "Expiration Time"), and the Offer was not extended.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220816005404/en/

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Gilead to Acquire Remaining Worldwide Rights of Trodelvy®

Gilead will Assume Responsibility for Clinical Development and Commercialization in Greater China and South Korea, among Other Asian Markets –

Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Everest Medicines to transfer all development and commercialization rights to Gilead for Trodelvy ® (sacituzumab govitecan) in Greater China, South Korea, Singapore, Indonesia, Philippines, Vietnam, Thailand, Malaysia and Mongolia.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Trodelvy® Significantly Improves Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in the TROPiCS-02 Study

Trodelvy is the First TROP-2 Directed ADC to Show a Significant Improvement in Overall Survival in HR+HER2- Breast Cancer –

Planned Second Interim Analysis Demonstrated a Statistically Significant and Clinically Meaningful Benefit for Overall Survival

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×